BLOG

psych

First Patient Dosed in Phase 3 Study of Psychedelic MM120 in Generalized Anxiety Disorder

MindMed announced the first patient had been dosed in the first-ever phase 3 trial of lysergic acid-diethylamide (LSD) for generalized anxiety disorder (GAD). MindMed is currently the furthest along in clinical trials exploring LSD as a treatment in multiple psychiatric indications, including major depressive disorder.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}